WallStSmart

Merck & Company Inc (MRK)vsSotera Health Co (SHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 5431% more annual revenue ($65.77B vs $1.19B). MRK leads profitability with a 13.6% profit margin vs 9.9%. SHC appears more attractively valued with a PEG of 1.68. SHC earns a higher WallStSmart Score of 68/100 (B-).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

SHC

Strong Buy

68

out of 100

Grade: B-

Growth: 7.3Profit: 8.0Value: 4.3Quality: 4.5
Piotroski: 4/9Altman Z: 0.71
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-40.6%)

Margin of Safety

-40.6%

Fair Value

$80.96

Current Price

$120.60

$39.64 premium

UndervaluedFair: $80.96Overvalued

Intrinsic value data unavailable for SHC.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$283.78B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

SHC2 strengths · Avg: 10.0/10
Operating MarginProfitability
31.3%10/10

Strong operational efficiency at 31.3%

EPS GrowthGrowth
175.4%10/10

Earnings expanding 175.4% YoY

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.4x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

SHC4 concerns · Avg: 3.0/10
PEG RatioValuation
1.684/10

Expensive relative to growth rate

P/E RatioValuation
39.5x4/10

Premium valuation, high expectations priced in

Free Cash FlowQuality
$-16.73M2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
0.712/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : SHC

The strongest argument for SHC centers on Operating Margin, EPS Growth.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : SHC

The primary concerns for SHC are PEG Ratio, P/E Ratio, Free Cash Flow. Debt-to-equity of 3.65 is elevated, increasing financial risk.

Key Dynamics to Monitor

SHC carries more volatility with a beta of 1.80 — expect wider price swings.

SHC is growing revenue faster at 10.0% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SHC scores higher overall (68/100 vs 50/100). Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Sotera Health Co

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Sotera Health Company provides sterilization, laboratory testing, and advisory services to the medical device, pharmaceutical, and food industries in the Americas, Europe, and Asia. The company is headquartered in Broadview Heights, Ohio.

Want to dig deeper into these stocks?